Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial.

ABSTRACT:

Objective

To determine whether comorbidity is associated with clinical (relapses, disability worsening) and MRI outcomes in multiple sclerosis (MS) by conducting a secondary analysis of the CombiRx clinical trial.

Methods

CombiRx compared interferon beta-1a, glatiramer acetate, and the combination of these agents. For participants eligible for evaluation of 6-month confirmed disability worsening, we used medical history, concomitant medications, and adverse events to ascertain comorbidity status. Comorbid conditions evaluated included hypertension, dyslipidemia, diabetes mellitus, depression, anxiety disorders, and migraine. Clinical outcomes included disease activity consisting of protocol-defined relapses, disability worsening, and MRI activity. We summarized the prevalenc

SUBMITTER: Salter A 

PROVIDER: S-EPMC9629214 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature